VRTX VERTEX PHARMACEUTICALS INC / MA

Price Chart

Executive Summary

Maxim Group upgraded Vertex Pharmaceuticals (VRTX) from Hold to Buy on March 18, 2026, setting a price target of $575, implying 34.6% upside from the current $427.38. The move is part of a cluster of 20 analyst actions on the stock, though most were maintains or initiations. Maxim’s track record is weak — correct on only 43% of 305 calls, with an average return of 5.9%. Consensus remains heavily bullish: 82.5% Buy rating (33 of 40 analysts), with a mean target of $548.39 and a high of $641. However, recent earnings estimate revisions are turning negative: 8 downgrades vs. 4 upgrades for FY2026 over the past 30 days, and 9 downgrades vs. 1 upgrade for FY2027. Insider selling has been persistent — five sells totaling ~$5M in March-April — and short interest sits at a high 62.7% of off-exchange volume. Institutional activity is mixed: FMR LLC trimmed large positions, while Norges Bank entered a new $1.44B stake. Earnings are due May 4, creating a near-term catalyst. The bullish analyst signal diverges from bearish insider and revision trends, suggesting limited conviction.

Impact Score

Consensus & Targets

Consensus is heavily bullish: 13 Strong Buy, 20 Buy, 6 Hold, 0 Sell, 1 Strong Sell across 40 analysts — equating to 82.5% Buy ratings. The lone Strong Sell comes from a single analyst. Direction is firmly positive, though the mix includes several holds, indicating some caution.

Mean price target: $548.39, median: $559.50, high: $641, low: $330. Current price $427.38 implies 28.3% upside to the mean and 30.9% to the median. Maxim’s $575 target is above the mean and median but below the high of $641, placing it in the top quartile of estimates.

Recent Analyst Activity

Analyst momentum is neutral on a 30-day count (0 upgrades, 0 downgrades), but the cluster includes one upgrade and one initiation, with most actions being maintains. EPS revisions are trending negative: FY2026 EPS estimates have 8 downgrades vs. 4 upgrades in the past 30 days; FY2027 has 9 downgrades vs. 1 upgrade. Net revisions are lower.

Firm Track Record — Maxim Group

Maxim Group accuracy: 43% on 305 calls | avg return: 5.9%

Industry benchmark: mean 51% ± 11%. Top tier: ≥61% (mean + 1σ). Based on 15 firms with ≥5 scored calls.

Maxim Group has a low accuracy rate of 43% on 305 scored calls, with an average return of 5.9%. Among firms covering VRTX with more than a few calls, the best performers are Truist Securities (75% on 4 calls), Citigroup (67% on 3), and Barclays (60% on 5). Maxim’s record is below average, reducing the weight of this upgrade.

Earnings Estimates

Next earnings: May 4, 2026

Cross-Platform Signals

Bearish signals diverge from the bullish analyst call. Insider selling: 5 transactions totaling ~$5.1M from March 4 to April 1, by executives including the CFO. Institutional: FMR LLC trimmed by 33% and 48% in separate filings; Renaissance Technologies trimmed 31%. Norges Bank entered a $1.44B new position, partly offsetting. Short interest is elevated at 62.7% ratio, indicating significant bearish positioning. Earnings are on May 4, creating a binary catalyst.

Documents Analyzed

Report based on filing metadata.

US Market Status